DWI参数联合RECIST 1.1早期评估肺癌骨盆骨转移疗效
本研究回顾性纳入27例肺癌骨盆骨转移患者78个病灶,分别在基线、治疗早期(<4个月)及晚期(6-15个月)行3次MRI。以晚期病灶大小变化为参考标准,通过ROC分析确定DWI反应阈值,并构建DWI-RECIST整合方案。结果显示DWI-RECIST较单纯RECIST有净分类增益且AUC更高,提示ADC参数对RECIST 1.1具有补充价值。
要点
- ADC>1300 µm²/s或ΔADC>0.14可定义为DWI反应。
- DWI-RECIST对RECIST归类为稳定病灶者更有补充价值。
- ADC测量观察者间一致性良好(ICC 0.83-0.86)。
核心结论
- DWI参数与RECIST 1.1整合可为肺癌骨盆骨转移疗效早期评估提供补充信息。
- 以晚期(6-15个月)病灶大小变化为参考标准时,DWI-RECIST较单独RECIST有净分类增益。
研究设计与样本
- 回顾性单中心研究,纳入2015年11月至2023年11月肺癌骨盆骨转移患者27例共78个病灶。
- 每例患者在基线、治疗早期(<4个月,TP1)及晚期(6-15个月,TP2)各接受一次MRI检查。
- 以TP2病灶大小变化为参考标准,通过ROC分析确定ADC阈值并定义DWI反应。
- 两名阅片者分别评估RECIST与DWI-RECIST早期反应,以TP2的RECIST结果为参考标准。
关键影像表现/征象
- DWI反应定义为ADC>1300 µm²/s或ΔADC>0.14。
- ADC值观察者间一致性良好,ICC为0.83-0.86。
诊断标准与关键数值
- 针对肺癌骨盆骨转移疗效评估,DWI反应阈值为ADC>1300 µm²/s或ΔADC>0.14。
- DWI-RECIST阅片者1较RECIST净分类增益7.4%,阅片者2净分类增益11.1%。
- DWI-RECIST的AUC较RECIST高(阅片者1:0.6964对0.6184,P=0.472;阅片者2:0.6415对0.6184,P=0.781)。
临床应用与阅片要点
- 对于RECIST 1.1归类为稳定病灶的骨转移病变,ADC或ΔADC超过上述阈值时提示有功能性反应。
- ADC测量重复性较好,适合在日常随访MRI中作为骨转移疗效评估的辅助量化指标。
局限性
- 本研究为回顾性单中心初步研究,样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine preliminary quantitative ADC thresholds for functional response and to evaluate whether integrating DWI metrics with RECIST 1.1 provides complementary information for early systemic therapy response assessment in bone metastases.
METHODS: This retrospective single-centre study included lung cancer patients with pelvic bone metastases who underwent three MRIs between November 2015 and November 2023: baseline, early time point (<4 months, TP1), and late (6-15 months, TP2) time points. ROC analysis based on lesion size change at TP2 determined ADC thresholds defining DWI response. A DWI response was defined as ADC >1300 µm²/s or ΔADC >0.14. An integrated response scheme (DWI-RECIST) combined this DWI-based response with RECIST assessment. Early responses at TP1 were compared between RECIST and DWI-RECIST using RECIST at TP2 as reference standard. Interobserver agreement was assessed using intraclass correlation coefficient, and diagnostic performance was evaluated using net reclassification improvement and AUCs.
RESULTS: Seventy-eight lesions from 27 patients were included. Compared with RECIST, DWI-RECIST yielded net classification gains of 7.4% (reader 1) and 11.1% (reader 2). DWI-RECIST showed higher AUCs than RECIST (reader 1: 0.6964 vs. 0.6184, p = 0.472; reader 2: 0.6415 vs. 0.6184, p = 0.781). Interobserver agreement for ADC was good (ICC 0.83-0.86).
CONCLUSIONS: Integrating ADC-derived DWI metrics with RECIST 1.1 may provide complementary information for early assessment of pelvic bone metastases from lung cancer, particularly in lesions categorised as stable disease.
ADVANCES IN KNOWLEDGE: This pilot study proposes quantitative ADC thresholds and introduces a framework integrating these with RECIST 1.1 to support more objective response assessment in lung cancer pelvic bone metastases.
引用
- Park, Lee, Lee, et al. Integrating DWI Parameters with RECIST 1.1 for Early Assessment of Systemic Therapy Response in Lung Cancer Pelvic Bone Metastases. Br J Radiol. 2026. PMID: 42898013. doi:10.1093/bjr/tqag249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。